Schering-Plough’s Maybelline
Executive Summary
Wasserstein Perella Partners agreed June 7 to purchase Maybelline at the same $300 mil. price tag that previous purchaser, MBP Acquisition Corp., originally offered. Schering announced May 7 that MBP had terminated its purchase of Maybelline. MBP includes the Playtex Family Products Corporation, Boston private investment firm Thomas H. Lee Company, as well as members of Maybelline and Playtex management, including Playtex President and CEO Joel Smilow. Wasserstein also announced that its $182 mil. acquisition of SmithKline Beecham's Yardley/Lentheric toiletries and cosmetics businesses has been completed.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.